Lupus Nephritis

Tacrolimus appears to have “synergistic” interactions with mycophenolate mofetil and cyclophosphamide for the treatment of renal involvement in systemic lupus erythematosus, according to observational data published in BMC Rheumatology.

WASHINGTON — Early triple therapy may be the most effective strategy for lupus nephritis, according to the new 2024 American College of Rheumatology Guideline for the Screening, Treatment, and Management of Lupus Nephritis.

SAN DIEGO — Help with transportation, copays and treatment adherence were the top three needs affecting health care according to a group of patients participating in a lupus navigator pilot program.

Early treatment with mycophenolate mofetil can reduce subsequent risks for severe flares and lupus nephritis in newly diagnosed systemic lupus erythematosus, according to data published in JAMA Network Open.

Repeat kidney biopsies may help patients with lupus nephritis manage disease flares, particularly those who transition between proliferative and non-proliferative disease classes, data from a racially diverse study cohort show.

Kezar Life Sciences has paused a phase 2b trial of zetomipzomib in active lupus nephritis after reporting four patient deaths, according to a press release from the manufacturer.

The FDA has granted fast track designation to CB-010, an allogeneic anti-CD19 CAR T-cell therapy from Caribou Biosciences, for refractory systemic lupus erythematosus ahead of a planned phase 1 trial, according to a press release.

Infections account for most in-hospital mortality in childhood systemic lupus erythematosus, with patients exhibiting lupus nephritis or end-stage renal disease at increased risk, according to data published in The Journal of Rheumatology.

The FDA has approved an investigational new drug application for Eque-cel, an autologous T-cell injection, in patients with systemic lupus erythematosus and lupus nephritis, according to a press release from the manufacturer.

Metformin may protect against the progression of adverse renal and cardiovascular outcomes in patients systemic lupus erythematosus, including lupus nephritis and infarction, according to data published in ACR Open Rheumatology.